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Despite recent remarkable advance in diagnosis and treatment, more than 40,000 patients 
die from breast cancer annually in the United States alone (Siegel et al., 2019). Majority of 
death is due to cancer recurrence and distant metastasis, where brain metastasis is the 
deadliest with a dismal 20% one-year survival (Kirsch et al., 2005). One of the reasons for 
this poor outcome is because of lack of effective treatment option other than radiotherapy, 
which is also not effective unless the lesion is localized. The development of novel 
therapeutics for breast cancer brain metastasis have been hampered by the lack of 
preclinical models that reliably reproduce clinical characteristics of human brain metastasis 
(Johnson et al., 2001). Commonly used rodent brain metastasis model is injection of cancer 
cells into the heart or carotid artery; however, this technique generates a scattered cluster 
of cancer cells rather than tumor mass that is morphologically very different from human 
metastatic brain tumor (Hausser et al., 2005). The patient-derived xenograft (PDX) model is 
a transplantation of human tumor tissue into the same (orthotopic) or different (ectopic) 
organ of immunodeficient mice. PDXs retain genomic, transcriptional and phenotypic 
features of the original tumor even after long-term continuous passage in vivo, and they are 
reported to relatively closely replicate drug response of a human tumor compared with 
syngeneic models (Mukohyama et al., 2016). Our group and the others demonstrated that 
cancer biology of orthotopic PDXs is closer to human tumor than subcutaneous PDXs 
(Okano et al., 2020); however, there was no established breast cancer brain metastasis 
PDX with high survival that provide stable results. In this thesis, I report the establishment 
of a novel orthotopic breast cancer brain metastasis PDX model that better mimics human 
cancer than the commonly used ectopic PDX, as well as further studies on the pursuit of 
clinical relevance of basic research findings. 
 
2. Materials & Methods 
I used breast cancer brain metastatic tumor resected from January 2017 to December 2019 
at the Roswell Park Comprehensive Cancer Center to establishment of the PDXs. One 
mm3 fragments of metastatic brain tumors of breast cancer patients were xenografted in 
brain caudate putamen or MFP of immunodeficient NSG mice using various methods. 
 
3. Results 
I tested 3 methods for tumor implantation in brain: direct placement of tumor fragment using 
fine forceps (Forceps method), and injection of gently crushed tumor fragment using 
beveled 23 G needle with syringe (Needle method) or a pipettor with 10-ul pipette tip of 1 
mm bore (Pipette method). PDXs in 8-10 mice were generated using each method. Post-
operative mortality was zero with the Forceps and Pipette methods. However, 5 of 8 mice 
died within a day of implantation with the Needle method. At 6 weeks post-implantation, 
tumors were detectable in 80%, 67%, and 100% of surviving mice implanted using the 
Forceps, Needle, and Pipette methods, respectively. Tumor volumes were less variable 
with the Pipette compared to the Forceps method. Unlike the 100% engraftment for brain 
PDXs, the engraftment rate of patient brain metastasis implanted ectopically in MFP was 
only 75%. However, both orthotopic and ectopic PDXs grew about 2-fold faster after 3x 
serial passaging (all t test p < 0.05). To assess the effect of tumor site on drug sensitivity, I 
compared response of the brain and MFP PDXs (n = 5 each) to one intravenous dose of 
Epothilone B, a taxane-like drug that can pass through the blood-brain barrier. While this 
drug is effective against primary breast tumors, it failed to demonstrate activity against 
breast cancer brain metastasis tumors in a recent phase II clinical trial. Tumor progression 
of MFP PDXs was retarded by approximately 3-fold compared to control mice (p < 0.05).  
On the other hand, the drug had no effect on brain PDXs (p = 0.95). Our result implicate 




I have established a novel orthotopic breast cancer brain metastasis PDX model that better 
mimics human cancer than the commonly used ectopic PDX. The advantage of our method 
is that only one cubic mm of tumor was sufficient for engraftment, and tumor growth was 
observed within almost all mice brains at one month after transplantation. This is important 
because it demonstrates that our method can be used to generate PDXs relatively quickly 
without wasting precious human specimens. Furthermore, with our method, passage 
number can be reduced by transplanting human specimens directly into the mouse brain 
with a high engraftment rate. In contrast to other methods, the pipette tip method I have 
developed has not only low postoperative mortality and high engraftment rates, but also 
provides more accurate positioning and smooth distribution of tumors during the transplant 
procedure. These are important factors as a preclinical model for patients with brain 
metastases who have not many times. Many studies have shown the usefulness of 
embedding tumors in Matrigel for tumor implantation. However, in the current study I 
observed that the growth of brain PDXs was significantly retarded by Matrigel compared to 
PBS. I could not find a previous citation of such an observation in the existing literature. 
The effect that I have observed could be because Matrigel inhibits tumor growth factors in 
the brain environment. As PDX tumors grow, their human tumor stroma is replaced by 
mouse stroma (Kluin et al., 2018). In our comparison of transcriptomes of original brain 
metastasis from one patient and its xenografts in mouse brain and MFP, I observed that 
approximately 15% of RNA transcripts of PDXs were murine. As expected from the loss of 
human stromal cells, overall human gene expression in both PDXs was significantly 
different from the patient’s tumor. These results show also that the tumor microenvironment 
can affect gene expression in cancer cells of the tumor. To investigate the drug response in 
this study, I used epothilone B, which has a high anti-cancer activity against primary breast 
cancer tumors and can cross the brain-blood barrier, however it failed a phase 2 clinical 
trial for effectiveness against breast cancer brain metastasis. In our study, while brain 
metastasis PDXs grown ectopically in mouse MFPs responded to the drug, with tumor 
growth retarded by about a third compared to untreated tumors, orthotopic PDXs did not 
respond to treatment. This results suggest that our newly established novel breast cancer 
brain metastasis PDX model mimicked the clinical trial result, thus, I can expect that our 
model can appropriately prevent ineffective compounds such as Epothilone B from entering 
the clinical trial and expose patients with unnecessary side effects when our model is used 
in preclinical studies.  
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